|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Haemophilus Influenza Infections | |||||
| Meningococcal Infection | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| Influenza, Human | |||||
| Meningococcal Infections | |||||
| 3 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Neisseriaceae Infections | |||||
| Orthomyxoviridae Infections | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Infections | |||||
| RNA Virus Infections | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Pediarix/Infanrix Penta | |||||
| ActHIB | |||||
| 5 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||